{
Ascendis Pharma A/S

Companies

}
001122334455554433221100
001122334455554433221100
Symbol ASND
Name Ascendis Pharma A/S
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country Denmark
State
City Hellerup
Zipcode 2900
Website http://www.ascendispharma.com
Track all markets on TradingView

ubs maintains buy rating for ascendis pharma with strong growth potential

UBS has reiterated its Buy rating for Ascendis Pharma, setting a price target of $196, amid strong sales growth and a positive outlook for its drug Yorvipath. Analysts project significant upside potential, with price targets ranging from $160 to $289, as the company approaches profitability and expands its product portfolio. Recent earnings results have prompted several firms to raise their price targets, reflecting confidence in Ascendis Pharma's market position and future growth prospects.
Investing.com Deutsch
United States Dollar Ascendis Pharma A/S USA
Business & Industry, Market Report
15:36 27.03.2025

ascendis pharma receives positive analyst ratings and targets for stock growth

Ascendis Pharma A/S is advancing its pipeline in endocrinology and oncology, with its SKYTROFA treatment for growth hormone deficiency. Analysts have given the stock a "Moderate Buy" rating, with price targets ranging from $170 to $289, indicating potential upside. The company has seen significant institutional investment, reflecting confidence in its growth prospects.
MarketBeat
Ascendis Pharma A/S DNK
Healthcare, Market Report
14:22 07.01.2025

ubs initiates buy rating on ascendis pharma with strong growth potential

UBS has initiated coverage on Ascendis Pharma with a Buy rating and a price target of $196, citing the company's strong position in the biotechnology sector and upcoming product launches. Analysts project that by 2035, revenues could reach €3.8 billion, driven by treatments for hypoparathyroidism, achondroplasia, and growth hormone disorders. They believe the market undervalues the potential of TransCon CNP and anticipate that the hypoparathyroidism treatment launch in 2025 may exceed expectations.
Investing.com
Euro Ascendis Pharma A/S DNK
Finance & Economy, Market Report
13:38 07.01.2025

ew immunosuppressive drug launched enhancing access for kidney transplant patients

A new generic immunosuppressive drug has been launched, enhancing access for kidney transplant patients. The global solid organ transplantation market is projected to grow, driven by innovations in transplantation methods, increased organ donation awareness, and tailored immunosuppressive treatments. North America is expected to dominate the market, while Asia-Pacific is poised for the fastest growth due to expanding healthcare infrastructure and rising public awareness.
Spherical Insights
United States Dollar GSK plc Bristol-Myers Squibb Company Johnsons and Johnsons Services Inc. Merck & Co., Inc. Leo Pharma A/S Mylan N.V. Ascendis Pharma A/S Teva Pharmaceutical Industries Ltd. Celltrion Inc. Hoffman-La Roche Ltd. ESP IND QAT GBR JPN KOR AUS ARE CHN DEU USA BRA RUS MEX CAN ARG FRA ITA SAU ZAF Show more
Healthcare, Market Report
04:04 19.11.2024

Ascendis Pharma reports strong Q3 results and strategic collaboration with Novo Nordisk

Ascendis Pharma reported strong Q3 2024 results, with total revenue of €57.8 million, driven by significant sales of SKYTROFA and the upcoming U.S. launch of YORVIPATH. The company plans to submit a New Drug Application for TransCon CNP in early 2025 and has formed a strategic collaboration with Novo Nordisk to advance treatments in metabolic and cardiovascular diseases. Despite a net loss of €99.2 million, Ascendis maintains a robust cash reserve of €625.5 million, indicating a positive outlook for future growth.
TipRanks Financial
Euro Ascendis Pharma A/S Novo Nordisk A/S DNK
Healthcare, Market Report
05:00 15.11.2024

novo nordisk partners with ascendis to develop long acting glp 1 drugs

Novo Nordisk has partnered with Ascendis Pharma to develop a long-acting GLP-1 drug and other metabolic treatments, potentially paying up to $285 million based on progress. Ascendis will receive additional fees for each drug developed, leveraging its delivery technology to reduce dosing frequency. The collaboration aims to enhance patient adherence to medications for obesity and diabetes, addressing high discontinuation rates in current treatments.
BioPharma Dive
Euro United States Dollar Ascendis Pharma A/S Novo Nordisk A/S Royalty Pharma plc DNK Brian Vandahl Royalty Pharma Show more
Finance & Economy, Market Report
17:52 04.11.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.